Welcome to our dedicated page for Lifestance Health Group news (Ticker: LFST), a resource for investors and traders seeking the latest updates and insights on Lifestance Health Group stock.
LifeStance Health Group, Inc. (LFST) provides investors and industry observers with timely access to corporate developments through this centralized news hub. Track official press releases, regulatory filings, and strategic announcements from one of the nation's leading outpatient mental healthcare providers.
Key resources include: Earnings reports detailing financial performance, partnership announcements with healthcare networks, expansions of clinical services, and leadership updates. This curated collection serves as a primary source for understanding LFST's operational milestones and market positioning.
All content reflects the company's focus on evidence-based behavioral healthcare and its commitment to expanding access through innovative care models. Regular updates ensure stakeholders stay informed about developments in teletherapy advancements, clinical research collaborations, and regulatory compliance matters.
Bookmark this page for direct access to LFST's verified corporate communications, eliminating the need to search multiple sources. Check back frequently for updates on operational metrics, facility expansions, and other material events shaping the company's trajectory in mental healthcare.
LifeStance Health Group announced a secondary public offering of 20 million shares of common stock by certain stockholders. The underwriters are given a 30-day option to purchase an additional 3 million shares. LifeStance will not sell any shares or receive any proceeds from this offering. The offering is made under a shelf registration statement filed with the SEC on May 21, 2024. Morgan Stanley, Goldman Sachs & TPG Capital are the underwriters. The prospectus is available on the SEC's website.
LifeStance Health Group, Inc. (Nasdaq: LFST) reported strong financial results for Q1 2024, with a revenue increase of 19% to $300.4 million, driven by higher visit volumes and improved revenue per visit. The clinician base also grew by 15%, reaching 6,866 clinicians. The company posted a net loss of $21.1 million, attributed to stock-based compensation, and an Adjusted EBITDA of $27.7 million. LifeStance reiterated its full-year revenue guidance of $1.19 billion to $1.24 billion, raising Center Margin expectations to $353 to $373 million, and Adjusted EBITDA to $88 to $98 million. The company also expects to maintain positive Free Cash Flow for the year.
FAQ
What is the current stock price of Lifestance Health Group (LFST)?
What is the market cap of Lifestance Health Group (LFST)?
